Clinical observation of dexmedetomidine nasal spray in the treatment of postoperative sleep disorders

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2100041597

Enrollment

Unknown

Registered

2021-01-01

Start date

2021-01-04

Completion date

Unknown

Last updated

2021-03-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Postoperative sleep disorders

Interventions

1:1ug/kg dexmedetomidine nasal spray

2:1.5ug/kg dexmedetomidine nasal spray

3:0.75ug/kg dexmedetomidine nasal spray

4:1.25ug/kg dexmedetomidine nasal spray

Eligibility

Sex/Gender

All

Age

18 Years to 40 Years

Inclusion criteria

Inclusion criteria: 1. 80 cases of maxillofacial surgery under general anesthesia and tracheal intubation; 2. Patients of either sex, aged 18-40 years, ASA grade I or II; 3. Patients who were left in the anesthesia recovery room for the first night after operation.

Exclusion criteria

Exclusion criteria: 1. Patients with other systemic diseases, such as congenital heart disease, hypertension and epilepsy. 2. Patients with severe sleep apnea syndrome, depression, use of sleep aid drugs and sedation and analgesia. 3. Patients with foreign body, tumor, polyp, abscess in respiratory tract and upper respiratory tract infection in recent 2 weeks. 4. Patients with hearing and speech impairment who can't cooperate and refuse to be enrolled.

Design outcomes

Primary

Measure	Time frame
Sleep rhythm;	—

Countries

China

Contacts

Public ContactWang Ye

Plastic Surgery Hospital of Chinese Academy of Medical Sciences

wangyedeemail@126.com+86 15801597504

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026